Abstract The proliferation and apoptosis of cells in the placenta play a critical role in preeclampsia (PE) in which estrogen has been implicated via estrogen receptors (ERs). A novel ER, G-protein-coupled receptor 30 (GPR30), has recently been shown to be involved in PE. We investigated the basic levels of proliferation and apoptosis in normal placentae and placentae with PE and compared GPR30 expression levels between the two groups. We demonstrated that low GPR30 expression levels, more apoptosis, and less proliferation were associated with PE. Moreover, our in vitro study showed that both the selective GPR30 agonist G1 and the general ER agonist 17-β-estradiol were able to protect the placenta from hypoxia-reoxygenation injuries, resulting in decreased apoptosis and increased proliferation. Furthermore, this protective effect was abolished by the addition of the selective GPR30 inhibitor G15. These results provide evidence that (1) GPR30 is involved in regulating cell proliferation and apoptosis; (2) pharmacologic upregulation of GPR30 is beneficial for PE management; (3) GPR30 may therefore be an interventional target for pregnancies complicated by PE.
Introduction
Preeclampsia (PE) is a disorder that is unique to human pregnancy, that is characterized by a generalized systemic maternal inflammatory response, and that is associated with diffuse cell dysfunction (Mol et al. 2015) . PE affects between 2 to 8 % of all pregnancies and is one of the leading causes of perinatal maternal and fetal morbidity and mortality (Grygiel-Gorniak and Puszczewicz 2016) .
Recently, deficient trophoblast invasion, which results in shallow implantation and poor placental perfusion, has been suggested to be the crucial step in PE development (Nandi et al. 2016 ). As prior research has shown, several factors play a role in this process. The imbalance of proliferation and apoptosis in the placenta is one key intermediary event that has been observed in the clinic. The rate of apoptosis is thought to increase in PE as a result of placental oxidative stress (Abimanyu 2014; Can et al. 2014) .
GPR30, also known as G-protein-coupled estrogen receptor (GPER1), combines with estrogen in humans and regulates the transcription of various estrogen genes (Maggiolini and Picard 2010) . GPR30 is widely distributed in the human body, and has been found in studies to be related to endometrial, ovarian, and breast cancer. GPR30 has also been demonstrated to have estrogen receptor properties with a high-affinity fastJianxin Li and Zhu Chen contributed equally to this work.
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response and a low capacity estrogen-binding site (Heino et al. 2008; Revankar et al. 2005; Thomas et al. 2005) . During pregnancy, the levels of both estrogen and progesterone are increased, and uteroplacental blood flow increases significantly to meet the nutrient requirements of fetal growth (Toda et al. 2013) . Estrogen has been reported to be of crucial importance during pregnancy, and GPR30 has been implicated in the rapid non-genomic effects of estrogens (Kolkova et al. 2010; Revankar et al. 2005) . GPR30 might modulate uteroplacental vascular function, since the plasma concentration of its ligand estrogen increases significantly during pregnancy, and an effect on vascular tone has been documented in many experimental and clinical contexts (Corcoran et al. 2014) . The vascular relevance of GPR30 function has been observed in human vascular endothelial cells, in which flow (shear stress) induces its expression (Takada et al. 1997) . In animal models, the inhibition of GPR30 expression reduces blood flow to the uteroplacental unit and results in fetal growth restriction and PE (Tropea et al. 2015) . Moreover, GPR30 plays a positive role in the proliferation and potential invasion related to breast cancer and cardiovascular disease (Lindsey and Chappell 2011; Meyer et al. 2011; Petrie et al. 2013; Scaling et al. 2014) . Activation of the AKT and ERK pathways has been found to be the link between GPR30, proliferation, and potential invasion (Welsh et al. 2012; Wrobel and Gregoraszczuk 2015) . Accumulating evidence implies that GPR30 has an important function not only in normal pregnancy, but also in some pregnancy complications such as PE (Mata et al. 2015; Tong et al. 2016) . However, the role of GPR30 in the pathophysiological changes of PE is poorly understood.
As in vivo hormone levels are known to change significantly during pregnancy, it is no surprise that complications of pregnancy such as PE occur (Reis et al. 2015 ). Hypoxiareoxygenation (H/R) is well-known to induce placental oxidative stress, which is one of the causes of PE (D'Souza et al. 2016; Sulistyowati 2014) . Therefore, we have used the H/R model as the template for our study (Du et al. 2012) ; we have investigated whether placental GPR30 expression is altered in PE, and whether H/R affects GPR30 expression, proliferation, and apoptosis.
Materials and methods

Tissue collection
Human placental tissues were obtained from women for immunohistochemical staining (IHC) and western blotting. Samples were obtained from ten primiparous women with PE. Placentae from these patients and from thirty normotensive primiparous women were collected after Caesarean section between February and August 2014 at the Department of Obstetrics & Gynecology of The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. These placentae were subdivided into two experimental groups. Group one consisted of 10 PE placentae and 10 normal placentae that were directly analysed by IHC and western blot. Group two included the remaining 20 normal placentae that were first employed as an H/R model, followed by western blotting and TUNEL assay. Human study was approved by the Ethics Committee of The First Hospital of Chongqing Medical University.
PE was defined as a maternal systolic blood pressure equal to or > 140 mmHg and/or a diastolic blood pressure of equal to or > 90 mmHg, measured on two occasions separated by at least 6 h, and proteinuria was defined as being > 300 mg on 24-h urinary collection or, qualitatively, > 1+, according to the guidelines of the American College of Obstetricians and Gynecologists (Jido and Yakasai 2013) . Patients with chronic medical conditions such as diabetes mellitus, cardiovascular disease, collagen disorders, chronic renal disease, chronic hypertension, and other metabolic diseases were excluded from this study.
All patients with PE were aged between 25 and 31 years, delivered at 36.1 ± 1.6 weeks, and were matched with normotensive deliveries. Chorionic and decidual surfaces were removed from all placental tissue, which was sampled from two placental lobules, either at the placental edge or midway between the edge and center of each placenta. Samples were washed with ice-cold phosphate-buffered saline (PBS) before storage in ice-cold Dulbecco's modified Eagle's medium (Gibco, Grand Island, N.Y., USA) and were transported to the laboratory within 30 min of surgery. (ab-120657, Abcam, Hong Kong, China) , the agonist of GPR30-G1 (G6798, Sigma, Saint Louis, USA), and the antagonist-G15 (G6548, Sigma) were dissolved in medium 199 (M2520, Sigma) at a concentration of 0.1 M and were stored at −20°C until required, when they were diluted to a working concentration by medium 199 at 0.1 mM, 0.01 mM, and 0.1 mM, respectively. GPR30 primer antibody (ab154069, Abcam) was diluted to 1:2000 in sterile PBS for western blotting and to 1:200 for IHC. Ki-67 antibody (ab15580, Abcam), active caspase 3 antibody (9661, CST), and active caspase 7 antibody (ab2323, Abcam) were diluted to 1:1500 in sterile PBS for western blotting and to 1:200 for IHC. Antibodies against AKT (9272, CST), p-AKT (4060, CST), ERK (4695, CST), p-ERK (4370, CST) were diluted to 1:1000 in sterile PBS for western blotting. In addition, β-actin (1:1000, ZSGB-BIO, TA-09) antibodies were used for western blotting. For the terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay, we used a TUNEL kit (11684795910, Roche, Germany).
Reagents and antibodies
E2
Tissue culture and treatment
Sampled tissues were dissected into small pieces (2-3 mm 3 ) and cultured in medium 199 (M2520, Sigma) supplemented with 20 % fetal bovine serum (FBS; 10099, GIBCO, Invitrogen), 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B. Tissues were treated with G1 (0.01 μM), G15 (0.1 μM), or E2 (0.1 μM) and incubated under various conditions. Normoxia was defined as 8 % O 2 , 87 % N 2 , and 5 % CO 2 at 37°C for 24 h. For H/R, these conditions were changed to hypoxia (2 % O 2 , 93 % N 2 , 5 % CO 2 , 37°C) for 8 h and reoxygenation (20 % O 2 , 75 % N 2 , 5 % CO 2 , 37°C) for 16 h. Experimental groups were assigned according to the various treatment arms as follows: CON (control), E2, G1, G15, E2 + G15, H/R, H/R + E2, H/R + G15, and H/R + E2 + G15 (Table 1 ). The concentrations of G1, G15, and E2 and the culture times were based on previous studies (Du et al. 2012 ).
Western blot
Proteins were extracted from tissues (50 mg) with RIPA buffer (Beyotime, P0013). Protein concentrations were determined by the use of a BCA Protein Assay Kit (Beyotime, P0010S), according to the manufacturer's instructions. Protein samples (1 μg/μl) were loaded onto 10 % (for GPR30, caspase 3, caspase 7, β-actin) or 8 % ( f o r P -A K T, A K T, P -E R K , E R K ) S D Spolyacrylamide gels, resolved by electrophoresis, and transferred to polyvinylidene difluoride membranes (0.45 mm, Millipore). Immunoblotting was performed by using primary antibodies against GPR30, caspase 3, caspase 7, P-AKT, AKT, P-ERK, ERK, and β-actin, respectively, followed by incubation with the appropriate horseradish-peroxidase (HRP)-linked secondary antibodies (1:1000, Beyotime). The chemiluminescence of target proteins on the membranes was developed with BeyoECL Plus (P0018, Beyotime). The densometric analyses of bands were performed by using a Chemidoc imager (Fusion FX5, ViberLourmat, France). β-Actin was used as the loading control.
Immunohistochemistry
Placental expression of GPR30, caspase 3, caspase 7, and Ki-67 in tissue that had not been cultured was determined by IHC of paraffin-embedded sections. Nonspecific antibody binding was blocked by incubation with 10 % normal goat serum for 60 min. Rabbit antihuman monoclonal antibody was then added, and samples were incubated overnight at 4°C. Sections were subsequently washed with PBS three times and incubated with biotin-conjugated goat anti-rabbit IgG for 120 min at 37°C, followed by treatment with HRP-labeled streptavidin for 30 min at 37°C. After being washed, sections were incubated with 3, 3′-diaminobenzidine (DAB; chromogenic reagent, ZSGB-BIO, China) and counterstained with hematoxylin. The negative control experiment was performed by replacing the primary antibody with goat serum or with IgG from the same species in which the primary antibodies had been generated. Sections were viewed and photographed under various magnifications (AXIO Observer.A1, Zeiss, Germany).
TUNEL assay
Apoptosis in cultured tissue was determined by a TUNEL assay, which was performed sequentially on the same placental sections. Formaldehyde-fixed frozen-embedded sections were pretreated with 20 μg/ml proteinase-K in 10 mM TRIS-HCl for 15 min and blocked with 10 % normal goat serum. After being washed, the sections were incubated with biotinylated goat anti-rabbit IgG (1:200, Vector Laboratories, US) for 30 min, washed again, and incubated with Texas Red streptavidin (10 μg/ml, Vector Laboratories) for 90 min. The TUNEL assay was performed with a commercial kit that labels DNA strand breaks with fluorescein isothiocyanate (In Situ Cell Death Table 1 Experimental design (PE preeclampsia, + assigned treatment, − no treatment, CON control, H/R hypoxia and reoxygenation, G1 GPR30 agonist, G15 GPR30 antagonist, E2 GPR30 agonist)
Treatment
Normal group PE group
Detection Kit 11684795910, Roche, Germany). Sections were mounted with Vectashield containing DAPI (4,6-diamidino-2-phenylindole; Vector Laboratories) and observed on a Leica TCS-NT-UV confocal microscope. Negative controls were obtained by substitution of the primary antibody with non-immune rabbit IgG or omission of the enzyme TdT. The rate of positive cells was calculated by counting the ratio between apoptotic cells and the total number of cells in the three selected areas from the middle region of each image (Table 2) .
Statistical analysis
Data are presented as the means ± standard deviation (SD). The difference between means was assessed by a Student t-Test by using the Graphpad Prism software package (version 5.0). A P-value < 0.05 was considered to be statistically significant.
Results
Differences in expression levels of GPR30, proliferation, and apoptosis between placentae with or without PE GPR30 expression was higher in placentae from normotensive primiparous women compared with that of PE as assessed by western blotting (Fig. 1 , t-test, *P < 0.05). However, this difference between the two groups was not observed by IHC (Fig. 1) . Normal placentae contained several ki-67-positive cells, but these were difficult to find in PE placentae (Fig. 1) ; this same tendency was seen on western blotting (Fig. 1 , t-test, *P < 0.05). Active caspase 3 and active caspase 7 expression was increased in PE placentae compared with the normal placenta (Fig. 1) . However, a greater change was seen in caspase 7, and western blotting confirmed a more specific transformation in caspase 7 (Fig. 1 , t-test, **P < 0.01) compared with caspase 3 (Fig. 1 , t-test, *P < 0.05). The results from fresh tissue were treated as control values.
Apoptosis was increased in PE according to extravillous explant culture model TUNEL-positive nuclei were significantly higher under H/R compared with normal cells under reoxygenation or hypoxia (Figs. 2, 3) . In normal groups, the rate of positive cells in groups G15 and G15 + E2 was increased, whereas it was reduced by G1 and E2. G1 was more potent than E2 in suppressing apoptosis (Fig. 2) . A distinct increase could be found when G15 + E2 were used in combination, compared with G15 alone. Group G15 + H/R showed a higher increase than group G15 + E2 + H/R (Fig. 3) . No obvious increase was noted between the control and H/R + G1 groups, whereas an increase could be seen in the rest of the H/R groups compared with the control group. The most obvious increase was discerned between group H/R + G15 and the control group (Fig. 3) . Similar results were observed in our western blots (Figs. 2, 3, *P < 0.05).
Elevated apoptosis is associated with altered AKT and ERK signaling in placental explant PE model GPR30, AKT, and ERK pathways were analyzed by western blotting (Fig. 4) . Under basal conditions, GPR30 demonstrated an opposite trend when compared with the phosphorylation of AKT or ERK, i.e., the activation levels of the AKT and ERK pathways increased, whereas the expression level of GPR30 decreased. GPR30 expression was significantly decreased by H/R (Fig. 4) . We tested the activation rate of AKT and ERK. With regards to AKT in the normal groups, all groups were increased compared with the control group. However, the differences between each of the groups were not statistically significant. In the H/R groups, they also increased, but more growth was seen in the control group. Comparing the H/R + G1 and H/R + E2 groups with the H/R group, we could find no significant increase. An obvious increase was seen when we compared group H/R + G15 and group H/R + G15 + E2 (Fig. 4) . With regard to ERK, in the normal groups, all groups increased when compared with the control group. This increase was significantly higher than in the corresponding AKT group. In the H/R groups, group H/R + E2 showed no statistical difference from the control. Compared with group H/R, group H/R + G1 and group H/R + G15 decreased, whereas group H/R + G15 + E2 significantly increased (Fig. 4) .
Discussion
In the present study, we report that PE is associated with impaired proliferation and promoted apoptosis. Moreover, in an explant culture system, GPR30 expression is negatively correlated with apoptosis during H/R. The imbalance of proliferation and apoptosis occurs because of multiple factors related to shallow placental implantation and poor perfusion, which has long been assumed to be the key step of PE development (Redman 2014a (Redman , 2014b . The role of GPR30 in regulating cell proliferation and Fig. 1 Expression of GPR30, Ki-67, active Caspase 7, and active Caspase 3 in placenta. a, e Immunostaining of GPR30 in normal (N) and preeclampsia (PE) human placenta. b, f Immunostaining of ki-67 in normal and PE human placenta. Expression of ki-67 in the placenta shows proliferation in the normotensive group (b) and PE group (f). c, g Immunostaining of active caspase 7 in normal and PE human placenta. d, h Immunostaining of active caspase 3 in normal and PE human placenta. Active caspase 7 shows interim apoptosis, and active caspase 3 reveals terminal apoptosis. i Negative control. Magnification × 100. Bars 200 μm. Insets Higher magnification views of the boxed areas. Magnification × 400. Bars 100 μm. j Western blot for GPR30, ki-67, and active caspases 3 and 7. k-n Semi-quantitative immunohistochemistry analysis showed that the percentages of cells positive for active caspase 3 or 7 in PE placenta were all significantly decreased when compared with those for normal placenta; t-test, **P < 0.01 invasion has been extensively studied in relation to other disease states, such as in cancer cells (Jiang et al. 2015; Shang et al. 2015) . GPR30 has been found to be involved in the regulation of calmodulin binding and is activated by estrogen, by which vascular endothelial calmodulin network links modulate vascular function (Tran et al. 2016 ). In cancer and cardiovascular studies, GPR30 has also been shown to play a role in proliferation, apoptosis, and invasion (Meyer et al. 2011; Scaling et al. 2014) . However, the role of GPR30 in the imbalance of proliferation and apoptosis and PE development remains unknown. Trophoblast cells have long been assumed to share similar properties with cancer cells, especially with regard to invasion. However, an important difference is that cancer cells have persistent invasiveness, whereas trophoblast cells gradually decline with growth to avoid the excessive invasion of placental tissue into the uterus (Lindsey and Chappell 2011; Myatt and Roberts 2015; Wei et al. 2014) . Thus, the present study has been able to verify that GPR30 plays a role in regulating trophoblast proliferation and apoptosis, which might further influence uteroplacental vascular function and placental perfusion.
Proliferation and apoptosis are known to be present throughout the three trimesters of pregnancy, with the most obvious changes being found in the third trimester of PE (Erboga and Kanter 2015) . Third-trimester placental tissue culture has been examained in this study in order to measure GPR30 expression, proliferation, and apoptosis in (Table 1) as revealed by TUNEL (a, d, g, j, m) , and location of all nuclei as shown by DAPI (4,6-diamidino-2-phenylindole) staining (b, e, h, k, n) . Merged images (c, f, i, l, o) show the positive apoptotic cells.
Magnification × 100. Bars 25 μm. Insets Higher magnification views of the boxed areas. Magnification × 400. Bars 100 μm. p Analysis of rate of positive cells (apoptotic cells among normal cells); cell counts were performed (Table 2) . q, r Western blot results of active caspase 3 (ttest,*P < 0.05, **P < 0.01) normal and PE placentae. Caspase 7 is well-known as being one of the initial factors in the apoptosis pathway, whereas caspase 3 is a final factor (Kyathanahalli et al. 2015; Leslie et al. 2015; Turner et al. 2016) . We have tested apoptosis via active caspase 3 and active caspase 7 levels and proliferation via ki-67 levels. GPR30 expression and proliferation are reduced, whereas apoptosis is increased in PE compared with normal placentae.
Oxidative stress has recently been demonstrated to occur when hypoxic placental tissues are reoxygenated in vitro, an observation that is consistent with injury (as in PE), leading to an imbalance between proliferation and apoptosis (Turpin et al. 2015) . Moreover, the patterns of immunostaining suggest parallels between the resultant oxidative stress and the imbalance of proliferation and apoptosis in PE. Collectively, these findings indicate that H/R represents a suitable model for investigating the generation of placental proliferation and apoptosis in PE. Apoptosis has been revealed to be changed by either the GPR30 agonist or antagonist. Previous results suggest that estrogen is able to induce AKT phosphorylation and ERK phosphorylation in the myoblast (Ronda and Boland 2016) . Similarly, our study has demonstrated that the GPR30 antagonist G15 upregulates Akt phosphrylation in the trophoblast, whereas the GPR agonist elevates ERK phosphorylation, a result that is consistent with those of Welsh et al. (2012) . Their data indicate that GPR30 is critical for ERK activation, and that AKT is negatively modulated by GPR30-mediated signaling. (Table 2) . q, r Western blot results of active caspase 3 (t-test,*P < 0.05, **P < 0.01)
In addition, the antagonist of GPR30 was originally thought to lead to an increase in apoptosis, a harmful effect that should be abolished by co-incubation with the agonist of GPR30. However, we have not observed statistical significance when comparing group G15 with group E2 + G15 or group H/R + G15 with group H/R + E2 + G15. E2 is a general estrogen agonist, which not only activates GPR30, but also activates ERα and ERβ. Thus, the elevated apoptosis and reduced proliferation in E2 + G15 possibly results from the activation of ERα and ERβ. Activation of ERα and ERβ is known to be able to inhibit cell proliferation and to promote cell apoptosis. These effects can be clarified by utilizing a selective GPR30 agonist and antagonist or by genetic approaches for manipulating GPR30 expression in the cell model. Future studies should further explore the downstream signaling pathways that are regulated by GPR30 in the trophoblast and might unveil the molecular mechanisms that underlie PE development.
In conclusion, we have shown that GPR30 is expressed in human placenta, and that its expression is significantly impaired in PE. Moreover, GPR30 might play a role in regulating the balance between proliferation and apoptosis in trophoblast cells. Therefore, GPR30 could be a promising interventional target for PE treatment. Fig. 4 Effects of GPR30 on AKT and ERK pathways. a Western blotting to test the expression of GPR30, ERK, p-ERK, AKT, and p-AKT in each group. The classification of tissue groups is listed in Table 1 . b Analysis of western blotting to show GPR30 expression in each group. c Analysis of western blotting to show AKT and p-AKT expression in each group. Pathways were estimated by using p-AKT/AKT levels. d Analysis of western blotting to show ERK and p-ERK expression in each group. Pathways were estimated by using p-ERK/ ERK levels (t-test in b-d: *P < 0.05, # P < 0.05, **P < 0.01, ## P < 0.01). On testing this pathway, the last four groups (G1, G15, E2, G15 + E2) were all found to show an increase. In the H/R group, compared with the H/R + G1 and H/R + E2 groups, a slight increase was observed (P = ns); H/R + G15 and H/R + G1 + E2 were increased. No significant differences were seen between the H/R + G15 and H/R + G1 + E2 groups
